Biotech News

Heron Therapeutics Announces Third Quarter 2026 Financial Results

Heron Therapeutics (HRTX)Heron TherapeuticsEarnings

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2026 and recent corporate updates.

Related news

Heron Therapeutics

Acute-Care Medicines Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care. Its portfolio is designed for administration in hospitals, ambulatory surgery centers and infusion settings. ZYNRELEF ZYNRELEF is an extended-release local anesthetic combining bupivacaine and meloxicam for...

Recent company news

Stock data

Close
0.26 USD
Market cap
85.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States